Back to results
US 2026/0240950 A1Published application
Viral infection modulation in vaccinated subjects treated with granulocyte-macrophage colony-stimulating factor (gm-csf)
AssigneePartner Therapeutics, Inc.
InventorsIla JOSHI, Fiona GARNER
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the treating or preventing a viral infection in a subject who has received a viral vaccine with granulocyte-macrophage colony-stimulating factor.
Claims132
A method of treating a breakthrough viral infection, comprising:
- (a) selecting a patient who has received a vaccination to the virus and has one or more symptoms of the viral infection;
- and
- (b) administering an effective amount of a composition comprising a granulocyte-macrophage colony-stimulating factor (GM-CSF) agent.
A method for treating a vaccinated patient with a breakthrough viral infection, administering an effective amount of a composition comprising a granulocyte-macrophage colony-stimulating factor (GM-CSF) agent,
- wherein the effective amount is sufficient to induce a reduction of the viral load and/or viral infection symptoms.
Dependencies are inferred from the claim text.